Treatment of retinitis pigmentosa-related cystoid macular edema with intravitreous ranibizumab.
To report the results of the use of intravitreous ranibizumab for treatment of cystoid macular edema (CME) associated with retinitis pigmentosa (RP). Intravitreous ranibizumab was used to treat a patient with CME associated with RP who was unable to tolerate oral acetazolamide and did not respond to topical dorzolamide treatment. Visual acuity, clinical examination, and optical coherence tomography (OCT) were performed before and after treatment. Intravitreous ranibizumab improved best-corrected visual acuity (BCVA) and decreased central retinal thickness (CRT) with disappearance of cystic spaces on the OCT. There was recurrence of CME on discontinuation of injections. Intravitreous ranibizumab may be an effective therapy for reducing RP-related CME. Further studies are required to determine whether intravitreous ranibizumab is beneficial in the management of this disease.